Filtered By:
Drug: Rituxan
Vaccination: Pneomococcal Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 22 results found since Jan 2013.
Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases
Int Immunopharmacol. 2023 Jun 3;120:110342. doi: 10.1016/j.intimp.2023.110342. Online ahead of print.ABSTRACTWe conducted a single-centre retrospective cohort study in a French University Hospital between 2010 and 2018 to describe the risk of severe infectious event (SIE) within 2 years after the date of first rituximab infusion (T0) prescribed after the evidence of acquired hypogammaglobulinemia (gamma globulins [GG] ≤ 6 g/L) in the setting of autoimmune diseases (AID) other than rheumatoid arthritis. SIE occurred in 26 out of 121 included patients. Two years cumulative incidence rates were 12.7 % (95 % CI 5.1-23.9) in ...
Source: International Immunopharmacology - June 5, 2023 Category: Allergy & Immunology Authors: Xavier Boumaza Margaux Lafaurie Emmanuel Treiner Ondine Walter Gregory Pugnet Guillaume Martin-Blondel Damien Biotti Jonathan Ciron Arnaud Constantin Marie Tauber Florent Puisset Guillaume Moulis Laurent Alric Yves Renaudineau Dominique Chauveau Laurent S Source Type: research
Risk of infections in patients with pemphigus treated with rituximab versus azathioprine or mycophenolate mofetil: A large-scale global cohort study
CONCLUSION: Within the first 12 months after treatment, patients under rituximab experience an elevated risk of COVID-19, parasitic and CMV infections. Rituximab is associated with pneumonia, osteomyelitis, and viral diseases even beyond the first year after therapy. Pneumococcal vaccine and suppressive antiviral therapy should be considered even one year following therapy. No signal for elevated risk of tuberculosis, hepatitis B virus reactivation, pneumocystis jiroveci pneumonia, and progressive multifocal leukoencephalopathy.PMID:36763798 | DOI:10.1093/bjd/ljac118
Source: The British Journal of Dermatology - February 10, 2023 Category: Dermatology Authors: Khalaf Kridin Noor Mruwat Kyle T Amber Ralf J Ludwig Source Type: research
Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy
CONCLUSIONS: Within 6 months of RIT, rates of survival without severe infection were similar in newly diagnosed ANCA-positive AAV patients treated with RTX or CYC, but survival rates without infections of any severity appeared to be lower with RTX treatment.PMID:35048797 | DOI:10.1080/03009742.2021.2001929
Source: Scandinavian Journal of Rheumatology - January 20, 2022 Category: Rheumatology Authors: M G érard H de Boysson R Morello N Martin-Silva A-C Leroux A Dumont G Maign é J Boutemy K Khoy D Mariotte T Lobbedez A Aouba S Deshayes Source Type: research
